rhenium-186 hedp has been researched along with Prostatic Neoplasms, Castration-Resistant in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beeker, A; Bloemendal, HJ; de Klerk, JMH; Hoekstra, OS; Jonker, MA; Los, M; O'Sullivan, JM; Oprea-Lager, DE; van den Berg, HP; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
| Bloemendal, HJ; de Klerk, JM; Hoekstra, OS; Hooft, L; Jong, JM; Oprea-Lager, DE; van den Eertwegh, AJ; Verheul, HM | 1 |
| Chittenden, SJ; Dearnaley, DP; Denis-Bacelar, AM; Divoli, A; Du, Y; Flux, GD; Johnson, B; McCready, VR; O'Sullivan, JM | 1 |
| Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
1 review(s) available for rhenium-186 hedp and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Topics: Antineoplastic Agents; Bone Neoplasms; Cancer Pain; Etidronic Acid; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; Strontium; Strontium Radioisotopes | 2016 |
2 trial(s) available for rhenium-186 hedp and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organometallic Compounds; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
1 other study(ies) available for rhenium-186 hedp and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Phase I/II trials of
Topics: Bone Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Etidronic Acid; Humans; Male; Organometallic Compounds; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Survival Analysis; Tomography, Emission-Computed, Single-Photon | 2017 |